{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:08:14Z","timestamp":1788782894433,"version":"build-2803163510"},"reference-count":38,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-162243"],"award-info":[{"award-number":["PJT-162243"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-180299"],"award-info":[{"award-number":["PJT-180299"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-180300"],"award-info":[{"award-number":["PJT-180300"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gastrin-releasing peptide receptor (GRPR) shows elevated expression in several malignancies and represents an attractive target in cancer imaging and radioligand therapy. However, improving in vivo stability without compromising high tumor uptake and low pancreatic uptake remains a key challenge for the development of GRPR-targeted radiopharmaceuticals. In the present study, we investigated whether incorporating unnatural amino acid substitutions at potential cleavage sites of the previously reported GRPR-targeted agonist [68Ga]Ga-SP01011 (Ga-DOTA-Pip-d-Phe-Gln7-Trp8-Ala9-Val10-Gly11-His12-Leu13-Ac6c14-NH2; Ac6c: 1-amino-1-cyclohexanecarboxylic acid) could enhance in vivo stability without compromising tumor-targeting capability. SP01012, SP01013, and SP01019 incorporating NMe-His12, Ala(tBu)13 and Tle10\/NMe-His12 substitutions, respectively, were synthesized by Fmoc solid-phase peptide synthesis and obtained in 22\u201360% yield. Their corresponding nonradioactive Ga complexes were obtained in 58\u201389% yield by reacting the DOTA-conjugated precursors with excess GaCl3 in acetate buffer, and the products were subsequently purified by HPLC. In vitro competition binding assays demonstrated that the Ki values of Ga-SP01012, Ga-SP01013 and Ga-SP01019 were 1.36 \u00b1 0.12, 11.5 \u00b1 0.89 and 2.29 \u00b1 0.77 nM, respectively. All three ligands retained agonistic characteristics as confirmed by the calcium release assay. Their 68Ga-labeled analogs were obtained by reacting the precursors with [68Ga]GaCl3 in HEPES buffer with microwave heating (100 \u00b0C, 1 min). Following HPLC purification, 68Ga-labeled tracers were obtained in 33\u201347% decay-corrected radiochemical yield with radiochemical purities &amp;gt;95%. PET\/CT imaging together with ex vivo biodistribution analyses conducted at 1 h postinjection in PC-3 tumor-bearing mice demonstrated clear tumor visualization and predominantly renal excretion for all three tracers. Among them, [68Ga]Ga-SP01012 containing the NMe-His12 substitution alone, had the most favorable profile, with the highest tumor uptake (15.8 \u00b1 0.65% ID\/g), low pancreas uptake (1.27 \u00b1 0.32% ID\/g), and improved in vivo plasma stability (78.1 \u00b1 0.83% intact tracer at 15 min postinjection compared to 63.5 \u00b1 6.24% for [68Ga]Ga-SP01011). In contrast, [68Ga]Ga-SP01019, containing both Tle10 and NMe-His12 substitutions, showed the highest plasma stability (88.3 \u00b1 2.90% intact tracer at 15 min postinjection), but this was accompanied by lower tumor uptake (12.4 \u00b1 1.54% ID\/g) and markedly increased pancreas uptake (23.7 \u00b1 3.47% ID\/g). [68Ga]Ga-SP01013, containing the Ala(tBu)13 substitution, showed reduced GRPR binding affinity and lower tumor uptake (8.33 \u00b1 1.41% ID\/g). Our findings indicate that [68Ga]Ga-SP01012 is a potential PET tracer for visualizing GRPR-expressing tumors, and the NMe-His12 substitution is a favorable modification for the design of GRPR-targeted agonist-based radiopharmaceuticals.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00854","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:01:40Z","timestamp":1786042900000},"page":"4770-4781","source":"Crossref","is-referenced-by-count":0,"title":["Unnatural\nAmino Acid Substitutions to Improve In Vivo\nGRPR-Targeting Capability of [68Ga]Ga-SP01011 for Cancer\nImaging"],"prefix":"10.1021","volume":"23","author":[{"given":"Sheetal","family":"Pathania","sequence":"first","affiliation":[{"name":"BC Cancer Research Institute , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 1L3"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Cheng","family":"Chen","sequence":"additional","affiliation":[{"name":"BC Cancer Research Institute , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 1L3"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Ng","sequence":"additional","affiliation":[{"name":"BC Cancer Research Institute , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 1L3"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Merkens","sequence":"additional","affiliation":[{"name":"BC Cancer Research Institute , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 1L3"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing Sum","family":"Lau","sequence":"additional","affiliation":[{"name":"BC Cancer Research Institute , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 1L3"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1510-9653","authenticated-orcid":true,"given":"Joseph","family":"Lau","sequence":"additional","affiliation":[{"name":"BC Cancer Research Institute , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 1L3"]},{"name":"University of British Columbia , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 1M9"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7995-3581","authenticated-orcid":true,"given":"Franc\u0327ois","family":"Be\u0301nard","sequence":"additional","affiliation":[{"name":"BC Cancer Research Institute , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 1L3"]},{"name":"University of British Columbia , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 1M9"]},{"name":"BC Cancer , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 4E6"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0739-0780","authenticated-orcid":true,"given":"Kuo-Shyan","family":"Lin","sequence":"additional","affiliation":[{"name":"BC Cancer Research Institute , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 1L3"]},{"name":"University of British Columbia , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 1M9"]},{"name":"BC Cancer , , , ,","place":["Vancouver, British Columbia, Canada, V5Z 4E6"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"2026090707080535500_cit1","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1007\/s00259-026-07780-y","article-title":"Prospective head-to-head comparison\nof [68Ga]Ga-RM2 PET\/CT and [68Ga]Ga-PSMA-617\nPET\/CT in newly diagnosed patients with intermediate-risk localized\nprostate cancer","volume":"53","author":"Perozziello","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026090707080535500_cit2","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70043","article-title":"Potential targets and\nbiomarkers of radionuclide therapy in breast cancer","volume":"5","author":"Tan","year":"2026","journal-title":"Cancer Innovation"},{"issue":"1","key":"2026090707080535500_cit3","doi-asserted-by":"publisher","first-page":"2320301","DOI":"10.1080\/07853890.2024.2320301","article-title":"Gastrin-releasing peptide receptor\n(GRPR) as a Novel Biomarker and therapeutic target in prostate cancer","volume":"56","author":"Zhang","year":"2024","journal-title":"Ann. Med."},{"issue":"13","key":"2026090707080535500_cit4","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1007\/s00259-023-06364-4","article-title":"Side-by-Side Comparison\nof the two widely studied GRPR radiotracers, radiolabeled NeoB and\nRM2, in a preclinical setting","volume":"50","author":"Damiana","year":"2023","journal-title":"Eur. J. Nucl.\nMed. Mol. Imaging"},{"issue":"8","key":"2026090707080535500_cit5","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3390\/pharmaceutics17081000","article-title":"The impact\nof the injected mass of the gastrin-releasing peptide receptor antagonist\non uptake in breast cancer: Lessons from a Phase I Trial of [99mTc]Tc-DB8","volume":"17","author":"Bragina","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"2026090707080535500_cit6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13550-025-01301-y","article-title":"A Preclinical\nstudy on the influence of linkers in [68Ga]Ga-NOTA-X-RM26\nradiotracers for PET imaging of GRPR expression","volume":"15","author":"Olaniran Ha\u030akansson","year":"2025","journal-title":"EJNMMI Res."},{"key":"2026090707080535500_cit7","doi-asserted-by":"publisher","first-page":"109041","DOI":"10.1016\/j.nucmedbio.2025.109041","article-title":"Comparative\nevaluation of radiolabeled bombesin analogs [177Lu]Lu-AMBA\nand [177Lu]Lu-RM2 for targeting GRPR in glioblastoma model","volume":"146\u2013147","author":"Grzmil","year":"2025","journal-title":"Nucl. Med. Biol."},{"issue":"2","key":"2026090707080535500_cit8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1053\/j.semnuclmed.2024.01.004","article-title":"Gastrin-Releasing\npeptide receptor as a theranostic target in breast cancer: A systematic\nscoping review","volume":"54","author":"Baun","year":"2024","journal-title":"Semin. Nucl. Med."},{"issue":"1","key":"2026090707080535500_cit9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.107.07108","article-title":"International Union\nof Pharmacology. LXVIII. Mammalian bombesin receptors: Nomenclature,\ndistribution, pharmacology, signaling, and functions in normal and\ndisease states","volume":"60","author":"Jensen","year":"2008","journal-title":"Pharmacol. Rev."},{"issue":"9","key":"2026090707080535500_cit10","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1136\/gut.19.9.767","article-title":"A Gastrin releasing\npeptide from the porcine nonantral gastric tissue","volume":"19","author":"McDonald","year":"1978","journal-title":"Gut"},{"issue":"22","key":"2026090707080535500_cit11","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.3390\/cancers13225766","article-title":"Radiolabeled bombesin\nanalogs","volume":"13","author":"Mansi","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"2026090707080535500_cit12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13550-025-01325-4","article-title":"Molecular\ntargets and the emerging role of copper radionuclides in prostate\ncancer theranostics","volume":"15","author":"Rodrigues","year":"2025","journal-title":"EJNMMI Res."},{"issue":"supplement 2","key":"2026090707080535500_cit13","first-page":"79P","article-title":"Molecular imaging of bombesin receptors\nin various tumors by Ga-68 AMBA PET\/CT: First results","volume":"48","author":"Baum","year":"2007","journal-title":"J. Nucl. Med."},{"issue":"19","key":"2026090707080535500_cit14","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-12-3490","article-title":"In Vivo imaging\nof prostate cancer using [68Ga]-labeled bombesin analog\nBAY86\u20137548","volume":"19","author":"Ka\u0308hko\u0308nen","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"2026090707080535500_cit15","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.7150\/thno.14958","article-title":"Gastrin-releasing peptide receptor\nimaging in breast\ncancer using the receptor antagonist 68Ga-RM2 And PET","volume":"6","author":"Stoykow","year":"2016","journal-title":"Theranostics"},{"issue":"11","key":"2026090707080535500_cit16","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2967\/jnumed.120.259630","article-title":"PSMA- and\nGRPR-targeted PET: results from 50 patients with biochemically recurrent\nprostate cancer","volume":"62","author":"Baratto","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026090707080535500_cit17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.116.178889","article-title":"Theranostic\nperspectives in prostate\ncancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1:\nPreclinical and first clinical results","volume":"58","author":"Nock","year":"2017","journal-title":"J. Nucl.\nMed."},{"issue":"6","key":"2026090707080535500_cit18","doi-asserted-by":"publisher","first-page":"896","DOI":"10.2967\/jnumed.124.269132","article-title":"First-in-human serum stability studies\nof [177 Lu]Lu-AMTG: A step toward improved GRPR-targeted\nradiopharmaceutical therapy","volume":"66","author":"Felber","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026090707080535500_cit19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7150\/thno.13580","article-title":"In vivo stabilization of a gastrin-releasing\npeptide receptor antagonist enhances PET imaging and radionuclide\ntherapy of prostate cancer in preclinical studies","volume":"6","author":"Chatalic","year":"2016","journal-title":"Theranostics"},{"issue":"6","key":"2026090707080535500_cit20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178943","article-title":"Differential stability of therapeutic\npeptides with different proteolytic cleavage sites in blood, plasma\nand serum","volume":"12","author":"Bo\u0308ttger","year":"2017","journal-title":"PLoS One"},{"key":"2026090707080535500_cit21","doi-asserted-by":"publisher","first-page":"1501407","DOI":"10.3389\/fphar.2024.1501407","article-title":"Comprehensive\nreview on neprilysin (NEP) Inhibitors: Design, structure-activity\nrelationships, and clinical applications","volume":"15","author":"Zhang","year":"2024","journal-title":"Front.\nPharmacol."},{"issue":"1","key":"2026090707080535500_cit22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1475-2867-11-13","article-title":"Inverse\nbaseline expression pattern\nof the NEP\/neuropeptides and NF\u03baB\/proteasome pathways in androgen-dependent\nand androgen-independent prostate cancer cells","volume":"11","author":"Patrikidou","year":"2011","journal-title":"Cancer Cell Int."},{"issue":"6","key":"2026090707080535500_cit23","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1021\/bc9000189","article-title":"In vitro and in vivo metabolism of Lu-AMBA, a GRP-Receptor\nbinding compound, and the synthesis and characterization of its metabolites","volume":"20","author":"Linder","year":"2009","journal-title":"Bioconjugate Chem."},{"issue":"26","key":"2026090707080535500_cit24","doi-asserted-by":"publisher","first-page":"12664","DOI":"10.1073\/pnas.91.26.12664","article-title":"Potent bombesin\nantagonists with C-terminal Leu-\u03c8(CH2-N)-Tac-NH2 or its derivatives","volume":"91","author":"Cai","year":"1994","journal-title":"Proc. Natl. Acad.\nSci. U.S.A."},{"issue":"12","key":"2026090707080535500_cit25","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.3390\/molecules27123777","article-title":"68Ga-Labeled [Leu13\u03c8Thz14]Bombesin(7\u201314) derivatives: Promising GRPR-targeting\nPET tracers with low pancreas uptake","volume":"27","author":"Wang","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"2026090707080535500_cit26","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3390\/molecules28041977","article-title":"68Ga-labeled [Thz14]Bombesin(7\u201314)\nanalogs: Promising GRPR-targeting agonist PET tracers with low pancreas\nuptake","volume":"28","author":"Wang","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"2026090707080535500_cit27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s41181-024-00241-7","article-title":"Unnatural amino acid substitutions\nto improve in vivo stability and tumor uptake of 68Ga-Labeled\nGRPR-Targeted TacBOMB2 derivatives for cancer imaging with positron\nemission tomography","volume":"9","author":"Wang","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"12","key":"2026090707080535500_cit28","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1021\/acs.molpharmaceut.4c00952","article-title":"Synthesis and Evaluation of 68Ga- and 177Lu-labeled [Pro14 ]Bombesin(8\u201314) derivatives\nfor detection and radioligand therapy of gastrin-releasing peptide\nreceptor-expressing cancer","volume":"21","author":"Wang","year":"2024","journal-title":"Mol. Pharmaceutics"},{"issue":"3","key":"2026090707080535500_cit29","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1021\/acs.molpharmaceut.5c01683","article-title":"Synthesis and evaluation\nof novel 68Ga-labeled GRPR-targeted PET tracers derived\nfrom [ d -Phe6, Pro14 ]Bombesin(6\u201314)\nand [ d -Phe6, Des-Met14 ]bombesin(6\u201314)\nSequences","volume":"23","author":"Jozi","year":"2026","journal-title":"Mol. Pharmaceutics"},{"issue":"supplement 1","key":"2026090707080535500_cit30","first-page":"261075","article-title":"Effects of replacing the thioproline moiety in the\nGRPR-targeting PET tracer, [68Ga]Ga-TacBOMB2, with a 6-membered\nring-containing amino acid on GRPR targeting and pancreas uptake","volume":"67","author":"Pathania","year":"2026","journal-title":"J. Nucl. Med."},{"issue":"2","key":"2026090707080535500_cit31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1158\/0008-5472.CAN-14-1603","article-title":"In vivo radioimaging of bradykinin\nreceptor B1, a widely overexpressed molecule in human cancer","volume":"75","author":"Lin","year":"2015","journal-title":"Cancer Res."},{"issue":"4","key":"2026090707080535500_cit32","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3390\/molecules28041977","article-title":"68Ga-labeled [Thz14]Bombesin(7\u201314)\nAnalogs: Promising GRPR-targeting agonist PET tracers with low pancreas\nuptake","volume":"28","author":"Wang","year":"2023","journal-title":"Molecules"},{"issue":"13","key":"2026090707080535500_cit33","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.3390\/molecules29133102","article-title":"Synthesis and evaluation of the first 68Ga-labeled C-terminal hydroxamate-derived gastrin-releasing\npeptide\nreceptor-targeted tracers for cancer imaging with positron emission\ntomography","volume":"29","author":"Wang","year":"2024","journal-title":"Molecules"},{"issue":"6","key":"2026090707080535500_cit34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/j.1399-3011.1996.tb00871.x","article-title":"Alanine Scan\nand N-methyl Amide Derivatives\nof Ac-bombesin[7\u201314]. Development of a proposed binding conformation\nat the neuromedin B (NMB) and gastrin releasing peptide (GRP) Receptors","volume":"48","author":"Horwell","year":"1996","journal-title":"Int. J. Pept. Protein Res."},{"issue":"5","key":"2026090707080535500_cit35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/ph17050621","article-title":"Synthesis and evaluation of novel 68Ga-labeled\n[D-Phe6,Leu13\u03c8Thz14]Bombesin(6\u201314)\nanalogs for cancer imaging with positron emission tomography","volume":"17","author":"Wang","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"5","key":"2026090707080535500_cit36","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1021\/acs.bioconjchem.8b00225","article-title":"Radiometal-dependent\nbiological profile of the radiolabeled gastrin-releasing peptide receptor\nantagonist SB3 in cancer theranostics: Metabolic and biodistribution\npatterns defined by neprilysin","volume":"29","author":"Lymperis","year":"2018","journal-title":"Bioconjugate\nChem."},{"key":"2026090707080535500_cit37","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2019.21","article-title":"Neprilysin\nas a biomarker: challenges and opportunities","volume":"6","author":"Pavo","year":"2020","journal-title":"Card. Fail. Rev."},{"issue":"9","key":"2026090707080535500_cit38","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/annonc\/mdm058","article-title":"Gastrin-releasing\npeptide receptor\nas a molecular target in experimental anticancer therapy","volume":"18","author":"Cornelio","year":"2007","journal-title":"Ann. Oncol."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00854","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4770\/66450407\/acs.molpharmaceut.6c00854.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/9\/4770\/66450407\/acs.molpharmaceut.6c00854.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:18:28Z","timestamp":1788779908000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/9\/4770\/5249765\/Unnatural-Amino-Acid-Substitutions-to-Improve-In"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,6]]},"published-print":{"date-parts":[[2026,9,7]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00854","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}